NASDAQ:GMDA Gamida Cell Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gamida Cell Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $1.88 +0.14 (+8.05%) (As of 07/5/2022 11:04 AM ET) Add Compare Share Today's Range$1.71▼$1.8950-Day Range$1.73▼$2.7252-Week Range$1.67▼$6.41Volume1,749 shsAverage Volume294,324 shsMarket Capitalization$111.30 millionP/E RatioN/ADividend YieldN/APrice Target$13.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Gamida Cell MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside635.8% Upside$13.83 Price TargetShort InterestBearish6.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.22) to ($1.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.81 out of 5 starsMedical Sector732nd out of 1,428 stocksBiological Products, Except Diagnostic Industry120th out of 218 stocks 3.5 Analyst's Opinion Consensus RatingGamida Cell has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.83, Gamida Cell has a forecasted upside of 635.8% from its current price of $1.88.Amount of Analyst CoverageGamida Cell has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.79% of the float of Gamida Cell has been sold short.Short Interest Ratio / Days to CoverGamida Cell has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Gamida Cell has recently decreased by 1.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGamida Cell does not currently pay a dividend.Dividend GrowthGamida Cell does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GMDA. Previous Next 2.7 News and Social Media Coverage News SentimentGamida Cell has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Gamida Cell this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for GMDA on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Gamida Cell to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gamida Cell insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.60% of the stock of Gamida Cell is held by insiders.Percentage Held by Institutions47.12% of the stock of Gamida Cell is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gamida Cell are expected to grow in the coming year, from ($1.22) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gamida Cell is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gamida Cell is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGamida Cell has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GMDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter. Email Address About Gamida Cell (NASDAQ:GMDA) StockGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.Read More GMDA Stock News HeadlinesJuly 5, 2022 | americanbankingnews.comFinancial Review: Taysha Gene Therapies (NASDAQ:TSHA) & Gamida Cell (NASDAQ:GMDA)June 10, 2022 | finance.yahoo.comGamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of DirectorsJune 2, 2022 | seekingalpha.comGamida Cell completes rolling submission to the FDA for omidubicelJune 2, 2022 | finance.yahoo.comGamida Cell Completes Rolling Biologics License Application Submission to the FDA for OmidubicelJune 1, 2022 | finance.yahoo.comGamida Cell to Present Corporate Highlights at the Jefferies Healthcare ConferenceJune 1, 2022 | finance.yahoo.comGamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201May 17, 2022 | finance.yahoo.comGamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences ConferenceMay 10, 2022 | seekingalpha.comGamida Cell Ltd. (GMDA) Management on Q1 2022 Results - Earnings Call TranscriptMay 10, 2022 | finance.yahoo.comGamida Cell Reports First Quarter 2022 Financial Results and Provides Company UpdateMay 9, 2022 | seekingalpha.comGamida Cell Q1 2022 Earnings PreviewMay 5, 2022 | finance.yahoo.comGamida Cell Ltd. (NASDAQ:GMDA): When Will It Breakeven?May 5, 2022 | finance.yahoo.comGamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022May 3, 2022 | finance.yahoo.comGamida Cell Announces the Date of Its First Quarter 2022 Financial Results and WebcastApril 27, 2022 | seekingalpha.comGamida Cell stock falls a day after soaring on FDA lifting clinical hold on GDA-201April 27, 2022 | finance.yahoo.comGamida Cell Posts Updated Omidubicel Data In Blood Cancer PatientsApril 27, 2022 | finance.yahoo.comGamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem MeetingsApril 26, 2022 | nasdaq.comFDA Lifts Clinical Hold On Gamida's Cryopreserved Formulation Of GDA-201April 26, 2022 | finance.yahoo.comGamida Cell Shares Jump On FDA Nod To Cell Therapy Trial In Blood Cancer SettingsApril 26, 2022 | marketwatch.comGamida Cell Gets FDA Clearance for NDA for GDA-201 Lymphoma TreatmentApril 26, 2022 | seekingalpha.comGamida stock soars 32% as FDA lifts hold on GDA-201, to start trial for treating blood cancerApril 26, 2022 | finance.yahoo.comGamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201April 25, 2022 | finance.yahoo.comPermian Highway Pipeline Announces Binding Open Season for Expansion ProjectApril 25, 2022 | finance.yahoo.comGamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem MeetingsApril 25, 2022 | finance.yahoo.comGamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem MeetingsApril 20, 2022 | finance.yahoo.comKinder Morgan Increases Dividend to $0.2775 Per Share Per Quarter and Announces Results for First Quarter of 2022See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GMDA CUSIPN/A CIK1600847 Webwww.gamida-cell.com Phone(722) 659-5666FaxN/AEmployees166Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today7/05/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$13.83 High Stock Price Forecast$22.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+635.8%Consensus RatingBuy Rating Score (0-4)3 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-205.58% Return on Assets-58.85% Debt Debt-to-Equity Ratio2.87 Current Ratio3.55 Quick Ratio3.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book2.54Miscellaneous Outstanding Shares59,200,000Free Float57,661,000Market Cap$111.30 million OptionableNot Optionable Beta1.83 Gamida Cell Frequently Asked Questions Should I buy or sell Gamida Cell stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Gamida Cell stock. View analyst ratings for Gamida Cell or view top-rated stocks. What is Gamida Cell's stock price forecast for 2022? 6 brokers have issued 12-month price objectives for Gamida Cell's shares. Their GMDA stock forecasts range from $6.00 to $22.00. On average, they expect Gamida Cell's stock price to reach $13.83 in the next year. This suggests a possible upside of 635.8% from the stock's current price. View analysts' price targets for Gamida Cell or view top-rated stocks among Wall Street analysts. How has Gamida Cell's stock performed in 2022? Gamida Cell's stock was trading at $2.54 at the beginning of the year. Since then, GMDA shares have decreased by 26.0% and is now trading at $1.88. View the best growth stocks for 2022 here. When is Gamida Cell's next earnings date? Gamida Cell is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for Gamida Cell. How were Gamida Cell's earnings last quarter? Gamida Cell Ltd. (NASDAQ:GMDA) issued its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.34). During the same period in the previous year, the firm posted ($0.34) earnings per share. View Gamida Cell's earnings history. Who are Gamida Cell's key executives? Gamida Cell's management team includes the following people: Dr. Julian Adams Ph.D., CEO & Director (Age 67, Pay $707k)Mr. Shai Lankry CPA, M.B.A., Chief Financial Officer (Age 46, Pay $564k)Ms. Michele Ilene Korfin M.B.A., R.Ph., Chief Operating & Chief Commercial Officer (Age 50, Pay $510k)Dr. Ronit Simantov M.D., Chief Medical & Chief Scientific Officer (Age 57, Pay $581k)Dr. Jas Uppal, Chief Regulatory & Quality Officer (Age 54, Pay $476k)Mr. Joshua F. Patterson, Gen. Counsel & Chief Compliance Officer (Age 46)Mr. Paul Nee, VP of MarketingMr. Naftali Brikashvili CPA, Sr. VP Fin. & OperationsDr. Tracey Lodie Ph.D., Scientific Advisor & Consultant (Age 52)Mr. Vladimir Melnikov, Sr. VP of Global Operations & Manufacturing Who are some of Gamida Cell's key competitors? Some companies that are related to Gamida Cell include Aerie Pharmaceuticals (AERI), Aura Biosciences (AURA), Kodiak Sciences (KOD), C4 Therapeutics (CCCC), ADMA Biologics (ADMA), Humacyte (HUMA), Adagio Therapeutics (ADGI), HilleVax (HLVX), bluebird bio (BLUE), MeiraGTx (MGTX), Forma Therapeutics (FMTX), Caribou Biosciences (CRBU), Mesoblast (MESO), Tarsus Pharmaceuticals (TARS) and Vickers Vantage Corp. I (VCKA). View all of GMDA's competitors. What other stocks do shareholders of Gamida Cell own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Enerplus (ERF) and Novan (NOVN). When did Gamida Cell IPO? (GMDA) raised $50 million in an IPO on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager. What is Gamida Cell's stock symbol? Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA." How do I buy shares of Gamida Cell? Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Gamida Cell's stock price today? One share of GMDA stock can currently be purchased for approximately $1.88. How much money does Gamida Cell make? Gamida Cell (NASDAQ:GMDA) has a market capitalization of $111.30 million. The company earns $-89,790,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. How many employees does Gamida Cell have? Gamida Cell employs 166 workers across the globe. How can I contact Gamida Cell? Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The official website for Gamida Cell is www.gamida-cell.com. The company can be reached via phone at (722) 659-5666 or via email at irpr@gamida-cell.com. This page (NASDAQ:GMDA) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
